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Chemotherapy-induced nausea and vomiting (CINV) can be 
major problem for children with cancer. Children are especially 
vulnerable to electrolytes imbalance, dehydration and weight loss, and 
poor nutrition may affect their tolerance of additional chemotherapy. The 
experience of vomiting creates physical and emotional distress for child 
and family or carers: as early as 1983 it was shown that, for patients, 
treatment-related nausea and vomiting were among the most dreaded 
adverse effects[1]. The distress can affect the person’s normal activities 
and quality of life significantly[2]. 
Children receiving chemotherapy are not at equal risk for 
developing CINV. Individual characteristics and chemotherapeutic agents 
are among the factors affecting risk, and the later are probably the most 
significant (Anti-emetic Subcommittee of the Multinational Association of 
Supportive Care in Cancer (ASMASCC)[3][4]. Variation in the 
management of CINV in children exists nationally and internationally. 
The aim of the present study is to present finding from an audit 
undertaken at the national Irish pediatric Cancer centre of the use and 
effective of anti-emetic and the resulting change in the management of 
CINV. Nausea vomiting and retching must be clearly defined for accurate 
assessment as separate concepts[5][6]. 
 The objective of the study was to check out chemotherapy 
induced nausea and vomiting (CINV) and efficacy of antiemetics in 
children (<18 years of age) for pediatric cancers with chemotherapy 
regimens having moderate or high emetogenic potential. 
 
1.1 Objective 
To study chemotherapy induced nausea and vomiting (CINV) 
and efficacy of antiemetics in children (<18 years of age) treated for 
pediatric cancers with cancers chemotherapy regimens having moderate 
or high emetogenic potential. 
 
2. Material and Method 
The present study was a prospective observational, single 
centre study conducted in the Department of Pediatric Hematology 
Oncology at Rajiv Gandhi Cancer Hospital and Research Centre from 
November 2012 to May 2013. Chemotherapy cycles in subjects which 
met the eligibility criteria were studied for chemotherapy induced 
nausea and vomiting (CINV), using National Cancer Institute (NCI) 
Common Toxicity Criteria. The anti-emetic agents used were based on 
the emetogenic potential of the chemotherapy protocol. The main 
objective was to document the prescribing and administration of 
antiemetics and collect data on the incidence of CINV with the purpose of 
studying the effectiveness of antiemetic medication used. 
2.1 Inclusion Criteria 
1. Patients age < 18 years of age 
2. Patients has a prognosis >3 months 
3. Patients with confirmed diagnosis of pediatric solid tumors 





Introduction: Chemotherapy induced nausea and vomiting (CINV) can be a major problem 
for children undergoing cancer treatment. The experience of vomiting creates physical 
distress for child and family. the purpose of studying the incidence of chemotherapy 
induced nausea and vomiting (CINV) and analysing the use and effectiveness of anti-
emetics, and to suggest if any changes are required to optimize the management of CINV in 
this setting.  
Method: This was a prospective observational study, which assessed the current usage, 
Chemotherapy cycles in subjects, which met the eligibility criteria were studied for 
chemotherapy induced nausea and vomiting (CINV), using National Cancer Institute (NCI) 
Common Toxicity Criteria. A total of 50 patients who met the study criteria were enrolled in 
to the study. All the data pertaining to reason for the antiemetic agents used were based on 
the emetogenic potential of the chemotherapy protocols.  
Result and Discussion: It was observed in our study that use of ondansetrone was 
according to standard guidelines. Hence although fairly good control of emesis was 
recorded for moderate emetogenic regimens, strategies for further improvement in 
antiemetic schedule for high emetogenic schedules should be considered. vincristine-
actinomycin-cyclophosphamide had the highest rate of emesis while high dose 
methotrexate had the best control. 
Conclusion: Among the various chemotherapy schedules used, it was observed that rate of 
acute emesis control was poorest with vincristine-actinomycin-cyclophosphamide and best 
control was observed with high dose methotrexate. This observation may be kept in mind 
when planning the anti-emetic protocol for these regimes. 
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2.2 Exclusion Criteria 
      1. Solid tumor patients would be excluded 
      2. Critically ill patients in ICU or critical setting 
      3. Patients shifted to ICU from ward 
 
3. Result and Discussion 
3.1 Demographic details  
Among 50 patients of childhood cancer, 235 cycles of 
chemotherapy were studied. The gender incidence revealed that males 
constituted 66% and females 34%. The age distribution revealed that 
median age was  12 years; 18% of patients were <5 years of age, 24% 
percent of patients were 6-10 years of age, 38% of patients were 11-15 
years of age and 20% of patients  were >15 years of age. The different 
types of childhood tumors studied were Ewing’s sarcoma (38%), 
osteosarcoma (26%) rhabdomyosarcoma (8%) germ cell tumor (8%) 
medulloblastoma (6%) Wilms tumor (4%) retinoblastoma (2%) and 
neuroblastoma (2%) in reducing order of frequency. The details of the 
different chemotherapy regimens revealed that High dose Methotrexate 
(23%), Ifosfamide-Etoposide (22%), Vincristine-Adriamycin-
Cyclophosphamide (14%), Vincritine-Cyclophosphamide (13%), 
Cisplatin-Adriamycin (11%), Bleomycin-Etoposide-Cisplatin (7%), were 
the most frequently  administered chemotherapy regimen in reducing 
order of frequency.  
 
Table 1: Demographic and disease related features involved in 





Age( in years)  
   <5yr 9(18) 
   6-10yr 12(24) 
   11-15 19(38) 
   >15yr 10(20) 
Gender  
   Male 33(66) 
   Female 17(34) 
Diagnosis  
   Ewing’s sarcoma 19(38) 
   Osteosarcoma 13(26) 
   Germ cell tumor 4(8) 
   Rhabdomyosarcopma 4(8) 
   Synovial sarcoma 3(6) 
   Wilm’s tumor 2(4) 
   Retinoblastoma 1(2) 
   Medulloblastoma 3(6) 
   Neuroblastoma 1(2) 
Chemotherapy 
Cisplatin 100mg/m2/Adriamycin 75mg/m2 28(11.91) 
Vincristin 1.5mg/m2/Adriamycin 75mg/ 
m2/Cyclophosphamide 1.2mg/m2 
34(14.46) 
Vincristine 1.5mg/m2/ Actinomycin 2.5mg/m2 
/Cyclophosphamide 1.2-2.2mg/m2 
21(8.93) 
Vincristine 1.5mg/m2/Cisplatin 100mg/m2/Etoposide 
100mg/m2 
8(3.40) 
Ifosfamide 1.8mg/m2/Adriamycin 25mg/m2 4(1.70) 
Vincristine 1.5mg/m2/Cyclophosphamide 1.2mg/m2 13(5.53) 
Ifosfamide 1.8mg/m2/Etoposide 100mg/m2 53(22.55) 




Bleomycin 18mg/m2/Etoposide 100mg/m2/Cisplatin 
20mg/m2 
7(2.97) 
Cyclophosphamide1.2gm/m2 /Topotecan 1mg/m2 6(2.55) 
Vincristine 1.5mg/m2 1(0.42) 
3.2 The details of the antiemetic drug schedules that were used with 
the different types of chemotherapy protocols   
Ondansetrone was used in all cases; dexamethasone and 
aprepitant were additional antiemetic agents that were used in patients 
with high emetogenic potential. Among the highly emetogenic 
chemotherapy protocols, ondansetrone alone was administered in 10% 
of cycles, and both ondansetrone and aprepitent in 77%. For the 
moderate emetogenic chemotherapy protocols, ondansetrone alone was 
administered in 9% of cycles, and both ondansetrone and aprepitent in 
44%. For the Low emetogenic chemotherapy aprepitant was not used 
and Ondansetrone alone was used in all (100%) cycles. 
 






















10(10) 25(25) 13(13) 52(52) 
Cisplatin/Adriamycin 28 0(0) 3(10) 6(21) 19(67) 
Vincristine/Adriamycin/Cyclophosphamide 34 3(8) 18(52) 3(8) 10(29) 
Vincristine/Actinomycin/Cyclophosphamide (dose-2.2gm/m2) 17 0(0) 3(17) 1(5) 13(58) 
Vincristine/Cyclophosphamide 13 7(53) 1(7) 1(7) 4(30) 
Vincristine/Cisplatin/ Etoposide 4 0(0) 0(0) 2(50) 2(50) 
Ifosfamide/Adriamycin 4 0(0) 0(0) 0(0) 4(100) 
Moderate Emetogenic Chemotherapy 128 (54) 12(9) 35(27) 59(46) 22(17) 
Ifosfamide/Etoposide 53 1(1) 31(58) 3(5) 18(33) 
High Dose Methotrexate 54 1(1) 1(1) 52(96) 0(0) 
Vincristine/Actinomycin/Cyclophosphamide (dose-1.2gm/m2) 4 0(0) 2(50) 0(0) 2(50) 
Vincristine/Cisplatin/ Etoposide 4 4(100) 0(0) 0(0) 0(0) 
Vincristine/Carboplatin/ Etoposide 6 6(100) 0(0) 0(0) 0(0) 
Bleomycin/Etoposide /Cisplatin 7 0(0) 1(14) 4(57) 2(28) 
Low Emetogenic Chemotherapy 7 (3) 7(100) 0(0) 0(0) 0(0) 
Cyclophosphamide/ 
Topotecan 
6 6(100) 0(0) 0(0) 0(0) 
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3.3 Frequency of vomiting with different chemotherapy protocols  
Emesis free cycles were observed in 40% of high emetogenic 
chemotherapy schedule, 46% of moderate emetogenic chemotherapy, 
and 57% of low emetogenic chemotherapy. Anticipatory emesis was 
observed in 47% of high emetogenic chemotherapy cycles, and 75% of 
moderate emetogenic chemotherapy cycles, and 71% of low emetogenic 
chemotherapy. Acute emesis was observed in 46% of high emetogenic 
chemotherapy cycles and 75% of moderate emetogenic chemotherapy, 
and 71% of low emetogenic chemotherapy. Delayed emesis was observed 
in 55% of high emetogenic chemotherapy cycles 53% of moderate 
emetogenic chemotherapy, and 14% of low emetogenic chemotherapy. 
Rescue drug therapy was not required in 81% cycles of high emetogenic 
chemotherapy, 92% cycles of moderate emetogenic chemotherapy and 
none of the low emetogenic chemotherapy protocols. 
 
Figure 1: Graph showing high emetogenic potential data of 
chemotherapy induced emesis 
 
Figure 2: Graph showing Moderate emetogenic potential data of 







Figure 3: Graph showing Low emetogenic potential data in 
chemotherapy induced emesis 
 
 
3.4 Frequency of nausea with different chemotherapy protocols 
Nausea free cycles were observed in 45% of high, 30% of 
moderate and 58% of low emetogenic chemotherapy schedule. 
Anticipatory nausea free cycles were observed in 43% of high 
emetogenic chemotherapy cycles, 43% of moderate emetogenic 
chemotherapy 66% of low emetogenic chemotherapy. Acute nausea free 
cycles were observed in 32% of high emetogenic chemotherapy cycles, 
33% of moderate emetogenic chemotherapy and 66% of low emetogenic 
chemotherapy. Delayed nausea free cycles were observed in 38% of high 
emetogenic chemotherapy cycles, 28% of moderate emetogenic 
chemotherapy, 66% of low emetogenic chemotherapy. Rescue drug 
therapy was not required in 94% cycles of high emetogenic 
chemotherapy, 88% cycles of moderate emetogenic chemotherapy and 
none of the  low emetogenic chemotherapy protocols. 
 
Figure 4: Graph showing high emetogenic potential data in 
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Figure 5: Graph showing moderate emetogenic potential data in 
chemotherapy induced nausea 
 
Figure 6: Graph showing low emetogenic potential data in 




This was an observational study of CINV, among 50 patients, 
diagnosed with different types of pediatric solid malignancy, receiving 
235 cycles of chemotherapy. Of these, the high emetogenic chemotherapy 
constituted 42% of cycles and moderate emetogenic chemotherapy 54%.  
The antiemetic schedule involved ondansetrone in 100% of 
cycles and in combination with other agents in more than 90% of all 
chemotherapy cycles. The 5-HT3 anatgonist, aprepitant, was used in 
significantly larger number of high emetogenic chemotherapy as 
compared to moderate ones (77% vs 44%, p < 0.01). These observations 
were in sync with the National Comprehensive Cancer Network 
guidelines. It was observed that acute emesis was more frequently 
observed with high emetogenic chemotherapy in comparison with 
moderate emetogenic chemotherapy (54% vs 25%, p <0.001), this 
difference was statistically significant. Furthermore, the grade of 
vomiting was worse in high as compared to moderate emetogenic 
chemotherapy, as a CTC grade of ≥2 occurred in 33% vs 19% of cycles 
respectively with a significant p value of 0.02. Hence although fairly good 
control of emesis was recorded for moderate emetogenic regimens, 
strategies for further improvement in antiemetic schedule for high 
emetogenic schedules should be considered. The incidence of delayed 
emesis was similar for the high (45%) and moderate (48%) emetogenic 
chemotherapy (p=0.6, NS). This reveals need for better delayed emesis 
control. It is also emphasizes the importance of counseling parents to 
administer proper antiemetic after discharge. Dexamethasone is very 
effective for delayed emesis and we can ensure that these patients do 
receive it prophylactically. Among the various chemotherapy schedules 
used, it was observed that rate of acute emesis control was poorest with 
vincristine-actinomycin-cyclophosphamide and best control was 
observed with high dose methotrexate (p value was significant). This 
observation may be kept in mind when planning the anti-emetic protocol 
for these regimes.  
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